MedTrace Logo

Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept

NCT00927069 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2011-09-09

Study results available
· View outcomes & findings →

Summary

This study will provide data on additional therapeutic benefits in administering Adalimumab in patients with plaque psoriasis that showed an unsatisfactory response after at least 3 months of treatment with etanercept.

Conditions

Interventions

DRUG

Adalimumab every other week

Adalimumab 40mg injection every other week for 24 weeks

DRUG

Adalimumab Every Week

Adalimumab 40mg injection every week for the last 12 weeks of study.

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Innovaderm Research Inc.

    lead OTHER

Principal Investigators

  • Robert Bissonnette, MD · Innovaderm Research Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-09-30
Completion
2008-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00927069 on ClinicalTrials.gov